Significance of pioglitazone in the therapy of diabetes: Determining the current position;Positionsbestimmung zum stellenwert von pioglitazon in der diabetestherapie

Deutsche Medizinische Wochenschrift

Volumn 132, Issue 49, 2007, Pages 2650-2653

  Eckert, S ^a,b   Erdmann, Erland ^c   Lundershausen, R ^d   Forst, T ^e   Scherbaum, W A ^f   Schnell, O ^g   Standl, E ^g   Schumm Draeger, P M ^h   Tschope D ^b   Walter, H ⁱ   Weber, M ^j  

^a Institutsangaben am Ende der Arbeit ^*

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d Bundesverband Deutscher Diabetologen EV   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g Nstitut für Diabetesforschung   (Germany)

^h Chirurgische Klinik Munchen Bogenhausen   (Germany)

ⁱ KLINIKUM NÜRNBERG   (Germany)

^j JOHANNES GUTENBERG UNIVERSITY   (Germany)

more..

Author keywords

Cardiovascular risk; Pioglitazone; Rosiglitazone; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG EFFECT; FRACTURE; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FRACTURES, BONE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; OSTEOPOROSIS, POSTMENOPAUSAL; PPAR GAMMA; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 38049006392     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993115     Document Type: Review

References (30)

1. Ahmed W, Ziouzenkova O, Brown J et al. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med 2007; 262 (2): 184-198
2. Berhanu P, Kipnes MS, Khan MA et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006; 3 (1): 39-44
3. Chappuis B, Braun M, Stettler C et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007; 23 (5): 392-399
4. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164 (19): 2097-2104
5. Deeg MA, Buse JB, Goldberg RB et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30 (10): 2458-2464
6. Derosa G, D'Angelo A, Ragonesi PD et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31 (4): 375-383
7. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366 (9493): 1279-1289
8. Erdmann E, Charbonnel B, Wilcox RG et al. Pioglitazone Use and Heart Failure in Patients with Type 2 Diabetes and Preexisting Cardiovascular Disease: Data from the PROactive Study (PROactive 08). Diabetes Care 2007; 30 (11): 2773-2778
9. Erdmann E, Dormandy JA, Charbonnel B et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49 (17): 1772-1780
10. Erdmann E, Schneider CA, Yates J. Effects of pioglitazone in patients with type 2 diabetes and reduced glomerular filtration rate: an analysis from PROactive. Diabetes 2007; 56 (Suppl 1 ): A 178-
11. European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone http://www.emea.europa.eu/pdfs/human/press/pr/ 48427707en.pdf
12. Fachinformation actos® Stand August 2007
13. Fachinformation Avandia® Stand Januar 2007
14. Forst T, Pfützner A, Lübben G et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk - the PIOSTAT Study. Metabolism 2007; 56 (4): 491-496
15. GlaxoSmithKline (GSK). Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia (rosiglitazone maleate) tablets for type 2 diabetes mellitus (Letter to Health Cate Providers). February 2007Available from www.fda.gov/MedWatch/safety/ 2007/Avandia_GSK_Ltr.pdf
16. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28 (7): 1547-1554
17. Goodman SB, Jiranek W, Petrow E, Yasko AW. The effects of medications on bone. J Am Acad Orthop Surg 2007; 15 (8): 450-460
18. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes. N Engl J Med 2007; 357 (1): 28-38
19. Hsiao A, Worrall DS, Olefsky JM, Subramaniam S. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 2004; 20 (17): 3108-3127
20. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 (23): 2427-2443
21. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27 (6): 1496-1504
22. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370 (9593): 1129-1136
23. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298 (10): 1180-1188
24. Mele KD. Avandia® (rosiglitazone maleate) GlaxoSmithKline NDA 21-071 Supplement 022 FDA META-ANALYSIS. http://www.fda.gov/ohrms/dockets/ac/07/ slides/2007-4308sl-00-index.htm
25. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356 (24): 2457-2471
26. Reynolds K, Goldberg RB. Thiazolidinediones: beyond glycemic control. Treat Endocrinol 2006; 5 (1): 25-36
27. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298 (10): 1189-1195
28. Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38 (3): 865-873
29. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953
30. FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia http://www.fda.gov/bbs/topics/NEWS/2007/NEW01743.html